How Do the FDA's CSA Guidance and ISPE's GAMP 5 Align?

Computerized systems used in production and the quality management system need assurance proportional to their intended use and risk. This post explains how ISPE's GAMP 5 (Second Edition) and the FDA's Computer Software Assurance for Production and Quality System Software guidance fit together, so teams can scale testing and documentation without defaulting to one-size-fits-all validation.

Many organizations, especially medical device and cross–functional product teams, depend on software across design transfer, manufacturing, quality processes, and distribution. Patient safety and product quality are often at stake, and any lapse in performance can lead to investigation work, delayed release decisions, inconsistent records, or audit observations.

In February 2026, the FDA updated its CSA guidance to use terminology consistent with the Quality Management System Regulation (QMSR), which affects how teams describe scope, assurance activities, and supporting records in validation documentation. 

FDA guidance sets regulatory expectations, and ISPE’s GAMP 5 provides an industry framework for applying a risk-based approach across the lifecycle. Used together, they help teams scale assurance to intended use and risk while keeping decisions and evidence easy to explain.

Critical Thinking and CSA 

The CSA methodology describes a risk-based approach to help ensure that the software and automated data processing systems used in production, or in the quality management system, are fit for their intended use. This approach emphasizes critical thinking to align testing methodologies, rigor, and documentation with the level of risk, allowing for more efficient testing processes. 

Principles and Categories of GAMP 5

GAMP 5 provides a comprehensive framework for ensuring the compliance and reliability of GxP (Good Practice) computerized systems across the system lifecycle. It helps teams define appropriate lifecycle activities and evidence to ensure that systems comply with regulations and function effectively throughout their development and maintenance. This is achieved using a risk-based approach that considers potential risks at every stage of the product's lifecycle. Identifying and addressing risks early reduces rework during implementation and makes change control and inspections easier to support.

GAMP 5 encompasses four software categories designed to help determine an appropriate lifecycle and validation strategy. Each GAMP 5 category has specific principles and guidance tailored to ensure regulatory standards.

• Category 1: Infrastructure
• Category 3: Non-configured product (i.e., commercial off-the-shelf, or COTS)
• Category 4: Configured product
• Category 5: Custom application

Earlier GAMP versions included a separate Category 2—firmware. In GAMP 5, firmware is no longer treated as its own category and is addressed based on the nature and risk of the embedded software. 

ISPE released a new edition of the GAMP 5 guide in July 2022 (ISPE GAMP 5: A Risk-Based Approach to Compliant GxP Computerized Systems, Second Edition). The Second Edition retains the category model while expanding guidance on service providers, modern development approaches, and the use of tools and automation.

How Do CSA and GAMP 5 Align?

GAMP 5 and the CSA guidance share common objectives and principles, emphasizing risk management, a lifecycle perspective, and regulatory compliance. CSA guidance on choosing assurance activities based on risk complements GAMP 5 validation guidelines by helping teams align assurance methods to intended use. Below are the key shared objectives.

• Shared goals: Both GAMP 5 and CSA aim to ensure the quality and data integrity of computerized systems. The primary goal remains the well-being of patients.

• Risk-based approach: GAMP 5 and CSA stress the importance of applying a risk-based approach and critical thinking when defining how to address risk. Higher-risk use cases call for more rigorous testing and stronger evidence; lower-risk areas may justify simpler testing with a clear rationale. The objective is not to eliminate all risks but to manage them in a balanced and appropriate manner.

• Lifecycle perspective: Both guidelines emphasize a lifecycle perspective, advocating for continuous validation and assurance activities from system development through retirement to support reliability and data integrity.

• Practical application: Use CSA to determine the level and type of assurance needed for each intended-use area, then use GAMP 5 to organize lifecycle deliverables and records, so the approach stays consistent and easy to defend.

• Balanced approach: Both GAMP 5 and the CSA guidance promote a balanced approach to computer system validation and assurance. Striking the right balance is crucial. Overly cautious approaches may result in unnecessary paperwork and redundant testing "just to be sure." Over-validation consumes time and effort without improving assurance when the added detail isn’t tied to the risk.

• Automation and technology: Both stress working smarter, not harder. In practice, that can include adopting modern digital tools that support traceability, controlled workflows, and evidence capture aligned to a risk-based strategy.

The overlap between CSA and GAMP 5 is straightforward: intended use and risk determine the level of assurance, and the lifecycle structure maintains consistent evidence over time. In practice—especially for medical device teams responsible for production and QMS software—this typically comes down to establishing repeatable workflows for requirements, risk management, testing, and change impact.

Meeting CSA and GAMP 5 Requirements

ValGenesis Validation Lifecycle Suite (VLS) is a modern risk-based, data-driven solution. It supports functional capabilities commonly used to align with GAMP 5 (Second Edition) and can support CSA-aligned testing strategies.

Powered by Designer Manager technology, the system “right-sizes” validation efforts. Designer Manager helps teams define requirements and apply risk thinking early, then link requirements to tests and supporting records. It supports iterative work, so validation artifacts remain up to date as requirements change, and provides paperless workflows that can reduce manual errors when addressing requirements changes and other common validation challenges.

How Digital Validation Software Supports CSA

ValGenesis VLS simplifies key parts of the validation process: defining intended use, applying a risk-based approach, determining and implementing assurance activities, maintaining traceability, and creating the appropriate records. Examples include:

• Identify intended use: VLS empowers users to manage requirements in a library of reusable objects (requirements, test steps, etc.). This can expedite document development and improve consistency by allowing teams to assess requirements once and reuse them across multiple systems. After requirements are defined, teams can select the testing approach based on risk.

• Determine a risk-based approach: The solution supports Agile methodology and allows users to perform risk assessments at the requirement, functional, or system level to determine the appropriate level of validation, then balance testing efforts according to the associated risk score. VLS supports multiple testing methods, including ad hoc, exploratory, and unscripted testing.

• Determine and implement assurance methods and activities: VLS supports traceability through requirements traceability matrices, frameworks, and test execution features. It can route test development work to assigned owners and support consistent script development using user-defined forms. This can support data integrity expectations, including ALCOA+ principles.

• Create the appropriate record: VLS supports electronic test execution and deviation management to help maintain the validated state and complete validation records. Change-impact summaries can facilitate change management with required review and re-execution notifications. This helps keep testing focused on what changed, saving time and resources.

How Digital Validation Software Supports GAMP 5

ValGenesis VLS can help regulated companies meet the foundational system requirements needed for alignment with GAMP 5 (Second Edition) standards out of the box. These include:

• Support system classification by assessing software and hardware categories
  
  
• Support the lifecycle approach from design through risk-based validation
  
  
• Support critical thinking with a risk-based system and functional assessments for computerized systems
  
  
• Manage changes efficiently with documented impact assessments
  
  
• Support risk-based decision-making during test planning, operation, change control, and retirement
  
  
• Support Agile methodology for system development and efficient release management
  
  
• Support higher assurance for high-risk requirements
  
  
• Support repeatable test execution and evidence capture, with results retained as objective evidence
  
  
• Support periodic review

ISPE's GAMP 5 guideline and the FDA's CSA guidance align around the shared goal of ensuring the quality, reliability, and compliance of computerized systems.

By mapping intended use to risk and selecting assurance methods accordingly —then organizing deliverables and evidence using GAMP 5’s lifecycle structure —companies can meet regulatory expectations while avoiding unnecessary documentation and retesting. Tools like ValGenesis Validation Lifecycle Suite can support this approach by maintaining traceability, capturing evidence and approvals, and managing change impact so validation remains consistent over time.

Watch the video below to learn more about the ValGenesis Validation Lifecycle Suite.